Treosulfan (Trecondi)

Unknown Manufacturer

Treosulfan is under investigation in Allogeneic Haematopoietic Stem Cell Transplantation. Treosulfan has been investigated for the treatment of Lymphoblastic Leukemia, Acute, Childhood.

Generate AI report

Overview

Treosulfan is under investigation in Allogeneic Haematopoietic Stem Cell Transplantation. Treosulfan has been investigated for the treatment of Lymphoblastic Leukemia, Acute, Childhood.

Indications

Not Available

Brand Names

Trecondi

Technical identifiers

Chemical Formula: <dd class="col-xl-8 col-md-9 col-sm-8">C₆H₁₄O₈S₂</dd>
CAS Number: 299-75-2
UNII ID: CO61ER3EPI

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

LYOPHILISATE OF TREOSULFAN
EP 3856151 A1Applicant: MEDAC GES FUER KLINISCHE SPEZIALPRAEPARATE MBHPriority: 2018
CN
EP
US
WO
6 publications
Crystalline form of treosulfan
US 12286394 B2Applicant: MEDAC GES FUER KLINISCHE SPEZIALPRAEPARATE MBHPriority: 2018
CN
US
2 publications
Use of treosulfan and derivatives thereof for treating multiple sclerosis
US 7235590 B2Applicant: MEDAC KLINISCHE SPEZIALPRAEPPriority: 2002
US
2 publications
Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
US 7199162 B1Applicant: MEDAC KLINISCHE SPEZIALPRAEPPriority: 1999
US
Temperature controlled sustained-release injection comprising alkyl agent and method for preparing the same
CN 101273962 AApplicant: SHANDONG LANJIN BIOLOG ENGINEEPriority: 2007
CN

Drugs